普罗沙鲁胺治疗AR阳性转移性乳腺癌:开放标签多中心Ib期研究及生物标志物分析结果
这项开放标签、剂量扩展、多中心Ib期研究评估了普罗沙鲁胺在AR阳性转移性乳腺癌(IHC≥1%)患者中的初步疗效与安全性,45例患者接受200 mg或300 mg每日口服。39例可评估患者8周和16周疾病控制率均为25.6%,未观察到部分或完全缓解,200 mg/d被确定为II期推荐剂量,常见3/4级不良事件为天冬氨酸转氨酶升高和γ-谷氨酰转移酶升高(各8.9%)。
要点
- 45例经治AR阳性转移性乳腺癌患者中,39例可评估,8周和16周疾病控制率均为25.6%。
- 200 mg/d被确定为II期推荐剂量,6个月无进展生存率为19.6%。
- 三阴性亚组8周疾病控制率为38.5%,8周达缓解者中位无进展生存期9.1个月。
核心结论
- 普罗沙鲁胺在经重度治疗的AR阳性转移性乳腺癌患者中显示出初步抗肿瘤活性和良好耐受性,支持进一步研究。
研究设计与样本
- 开放标签、剂量扩展、多中心Ib期试验,纳入免疫组化AR≥1%的AR阳性转移性乳腺癌患者,口服普罗沙鲁胺每日一次。
- 两个剂量队列序贯研究:队列A 200 mg(n=30),队列B 300 mg(n=15),共45例患者,既往中位系统治疗线数为3线(范围1-13)。
- 主要终点为8周和16周疾病控制率及II期推荐剂量。
主要发现
- 39例可评估患者8周和16周疾病控制率均为25.6%(95%CI 11.9-39.4%),队列A为26.9%,队列B为23.1%。
- 无患者达到部分缓解或完全缓解。
- 6个月无进展生存率为19.6%(95%CI 10.2-37.5%)。
- 三阴性亚组8周疾病控制率为38.5%,8周达缓解者(n=5)中位无进展生存期为9.1个月(95%CI 7.8-NA)。
- 最常见3/4级不良事件为天冬氨酸转氨酶升高(8.9%)和γ-谷氨酰转移酶升高(8.9%)。
关键数值与推荐
- 普罗沙鲁胺200 mg/d被确定为II期推荐剂量。
- 生物标志物分析显示,AR免疫组化中度表达(26%-75%)、PIK3CA致病性突变或游离DNA产量<60 ng/ml的患者无进展生存期更长。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Proxalutamide is a novel second-generation non-steroidal androgen receptor (AR) antagonist. This study aimed to evaluate the preliminary efficacy and safety of proxalutamide in patients with AR-positive metastatic breast cancer (AR+ mBC). METHODS: In this open-label, dose-expansion, multicentre phase Ib trial, patients with AR+ mBC (immunohistochemistry [IHC] ≥1%) received proxalutamide orally once daily. Two proxalutamide dose cohorts (cohort A: 200 mg; cohort B: 300 mg) were sequentially investigated. Primary endpoints were disease control rate (DCR) at 8 and 16 weeks and recommended phase II dose (RP2D). RESULTS: Forty-five patients with three median lines (range, 1-13) prior systemic therapy were enrolled (cohort A, n = 30; cohort B, n = 15). Among 39 evaluable patients, DCR at 8 and 16 weeks was 25.6% (95% confidence interval [CI], 11.9-39.4%), with 26.9% in cohort A and 23.1% in cohort B. No patient achieved partial response or complete response. Proxalutamide 200 mg/day was determined as RP2D. The 6-month progression-free survival (PFS) rate was 19.6% (95% CI, 10.2-37.5%). In the triple-negative subgroup, DCR at 8 weeks was 38.5%, with median PFS of 9.1 months (95% CI, 7.8-NA) in those who achieved response at 8 weeks (n = 5). Most common grade 3/4 adverse events were aspartate aminotransferase increase (8.9%) and γ-glutamyltransferase increase (8.9%). By biomarker analysis, patients with moderate AR expression of IHC (26%-75%), PIK3CA pathogenic mutations, or <60 ng/ml cell-free DNA yield showed longer PFS. CONCLUSION: Proxalutamide showed promising anti-tumour activity with good tolerability in patients with heavily pretreated AR+ mBC, supporting further investigation. TRIAL REGISTRATION: This clinical study was prospectively registered at chinadrugtrials.org.cn (Identifier: CTR20170757) and clinical trials.gov (Identifier: NCT04103853).
引用
- Jiang H, Ouyang Q, Yin Y, et al. Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. Eur J Cancer. 2022. PMID: 36182805. doi:10.1016/j.ejca.2022.08.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。